论文部分内容阅读
表皮生长因子酪氨酸抑制剂是肺癌治疗中应用广泛的靶向药物,而其疗效的预测主要依靠有创的基因检测方法或粗略的临床估计。PET受体显像是集配体结合高特异性和放射性探测高敏感性于一体的显像技术。目前,以EGFR受体为靶点的PET显像研究正处于药物研发阶段,研究表明此种显像技术有助于建立肺癌靶向治疗疗效的无创性影像学检测,为肺癌的个体化治疗提供更多依据。
Epidermal growth factor tyrosine inhibitors are widely used in the treatment of lung cancer targeted drugs, and its prediction of the efficacy of mainly rely on invasive genetic testing methods or rough clinical estimates. PET receptor imaging is a set of ligand binding high specificity and radioactive detection of high sensitivity in one imaging technology. Currently, PET imaging targeting EGFR receptors is in the phase of drug development. Studies have shown that this imaging technique can help establish noninvasive imaging of lung cancer targeted therapies and provide personalized therapy for lung cancer More basis.